Welcome to our dedicated page for Ge Healthcare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.
The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.
GE HealthCare Technologies Inc. reported that its General Counsel and Corporate Secretary, Frank R. Jimenez, received new equity awards. He was granted an employee stock option covering 28,697 shares of common stock at an exercise price of $0.00 per share, and a separate award of 10,915 shares of common stock, reported as a grant or award acquisition.
The common stock award represents restricted stock units, each equal to one share of GE HealthCare common stock. For that award, 33% will vest on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock option vests on the same schedule, with 33% becoming exercisable on each of those first two dates and 34% on the third. After these transactions, Jimenez directly holds 28,697 employee stock options and 92,182 shares of common stock.
Kass-Hout Taha reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. reported that Chief Technology Officer Taha Kass-Hout received equity awards on March 2, 2026. He was granted an employee stock option for 34,847 shares and 13,254 shares of common stock as a restricted stock unit award, vesting in stages from September 2, 2027 through September 2, 2029.
GE HealthCare Technologies Inc. Chief People Officer Adam Y. Holton reported awards of company equity on March 2, 2026. He received an employee stock option for 14,348 shares of common stock at an exercise price of $0.00 per share, bringing his directly held options to 14,348.
On the same date, he was granted 5,457 shares of common stock, increasing his directly held common shares to 22,225. The common stock award consists of restricted stock units, with 33% vesting on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock options follow the same 33%/33%/34% vesting and exercisability schedule on those dates.
GE HealthCare Technologies Inc. Chief Accounting Officer George A. Newcomb reported equity awards from the company. He received an employee stock option for 3,443 shares of common stock at an exercise price of $0.00 per share, and an award of 1,309 restricted stock units, each representing one share of common stock at settlement.
According to the award terms, 33% of the restricted stock units will vest on September 2, 2027, another 33% on September 2, 2028, and the remaining 34% on September 2, 2029. The stock option becomes exercisable on the same schedule: 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. After these transactions, he directly owned 10,627 shares of common stock and had an additional 12 shares held indirectly by a family member.
GE HealthCare Technologies reported that Kevin Michael O'Neill, CEO of PDx, received equity awards on March 2, 2026. He was granted 17,218 employee stock options at an exercise price of $0.00 per share and 6,549 shares of common stock as a stock award, all held directly.
The options will become exercisable in three installments of 33%, 33%, and 34% on September 2, 2027, September 2, 2028, and September 2, 2029. A separate restricted stock unit award will vest on the same 33%, 33%, 34% schedule. O'Neill also has 59 shares held indirectly through a share incentive plan trust.
Rackliffe Philip reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. granted equity awards to executive Philip Rackliffe, CEO of AVS. He received 24,598 employee stock options with a right to buy GE HealthCare common stock and 9,356 restricted stock units, each representing one share upon settlement.
The stock options and restricted stock units vest over three years, with 33% vesting or becoming exercisable on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. These awards are part of his direct ownership and represent compensation rather than open-market purchases.
GE HealthCare Technologies Inc. reported that Roland Rott, CEO of Imaging, received new equity awards. He was granted employee stock options for 22,548 shares at an exercise price of $0.00 per share and 8,576 shares of common stock as a stock-based award.
The restricted stock units for 8,576 shares will vest in stages, with 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The 22,548 stock options follow the same 33%/33%/34% exercisability schedule on those dates.
SACCARO JAMES reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. reported that Chief Financial Officer James Saccaro received equity awards on March 2, 2026. He was granted 32,797 employee stock options and 12,475 restricted stock units, each at a price of $0.00 per unit.
The restricted stock units vest 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock options become exercisable on the same 33%/33%/34% schedule over those dates. Following the stock award, Saccaro directly holds 84,161 shares of common stock and 32,797 options.
Arduini Peter J reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. reported that President and CEO Peter J. Arduini received new equity awards. He was granted an employee stock option covering 129,140 shares of GE HealthCare common stock and 49,120 restricted stock units, each representing one share of common stock at settlement.
According to the vesting schedule, 33% of both the restricted stock units and the stock options will vest or become exercisable on September 2, 2027, another 33% on September 2, 2028, and the remaining 34% on September 2, 2029. Following the stock grant, Arduini directly owned 255,255 shares of common stock.
GE HealthCare Technologies Inc. entered into a new 364-day senior unsecured revolving credit agreement for $0.5 billion with JPMorgan Chase Bank and other lenders. This revolving credit facility matures on February 25, 2027 and can be drawn in U.S. Dollars, Euros, or Pound Sterling.
Borrowings bear interest at benchmark rates such as SOFR, EURIBOR, or SONIA, plus a margin tied to the company’s senior unsecured long-term debt ratings. The agreement includes customary covenants on liens, certain corporate transactions, leverage, and subsidiary indebtedness, along with standard events of default.
The new facility replaces a prior $0.5 billion 364-day revolving credit agreement dated March 27, 2025, which was terminated without penalty on February 26, 2026.